Pharmacogenetic testing: Proofs of principle and pharmacoeconomic implications

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 573, Issue 1-2, 2005, Pages 180-194

  Dervieux, Thierry ^a   Meshkin, Brian ^a   Neri, Bruce ^a  

^a Prometheus Laboratories   (United States)

Author keywords

Pharmacoeconomics; Pharmacogenetics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 6 MERCAPTOPURINE DERIVATIVE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABACAVIR; ANTIRETROVIRUS AGENT; AZATHIOPRINE; CYTOCHROME P450 2C9; DIHYDROPYRIDINE DEHYDROGENASE; FLUOROURACIL; FOLIC ACID; GENERIC DRUG; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; OXIDOREDUCTASE; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TIOGUANINE; UNCLASSIFIED DRUG; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CAUSE OF DEATH; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG COST; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MEDICARE; NEUROTOXICITY; PHARMACOGENETICS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; TOXICITY; TREATMENT FAILURE;

EID: 17044418894     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2004.07.025     Document Type: Review

References (110)

1. F. Vogel Moderne probleme der humangenetik Ergebnisse Inneren Medizin und Keinderheilkunde 12 1959 52 125
2. A.S. Alving, P.E. Carson, C.L. Flanagan, and C.E. Ickes Enzymatic deficiency in primaquine-sensitive erythrocytes Science 124 1956 484 485
3. W. Kalow The familial incidence of low pseudocholinesterase level Lancet 271 1956 124
4. D.A. Evans, K.A. Manley, and V.A. McKusick Genetic control of isoniazid metabolism in man Br. Med. 5197 1960 485 491
5. F.J. Gonzalez, R.C. Skoda, S. Kimura, M. Umeno, U.M. Zanger, and D.W. Nebert Characterization of the common genetic defect in humans deficient in debrisoquine metabolism Nature 331 1988 442 446
6. U.A. Meyer, and U.M. Zanger Molecular mechanisms of genetic polymorphisms of drug metabolism Annu. Rev. Pharmacol. Toxicol. 37 1997 269 296
7. I. Johansson, E. Lundqvist, L. Bertilsson, M.L. Dahl, F. Sjoqvist, and M. Ingelman-Sundberg Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine Proc. Natl. Acad. Sci. U.S.A. 90 1993 11825 11829
8. R. Sachidanandam, D. Weissman, S.C. Schmidt, J.M. Kakol, L.D. Stein, and G. Marth A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms Nature 409 2001 928 933
9. M.C. Dubinsky Monitoring of AZA/6-MP treatment in children with IBD is necessary Inflamm. Bowel Dis. 9 2003 386 388
10. M.C. Dubinsky, S. Lamothe, H.Y. Yang, S.R. Targan, D. Sinnett, and Y. Theoret Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gastroenterology 118 2000 705 713
11. L. Lennard, J.S. Lilleyman, J. Van Loon, and R.M. Weinshilboum Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia Lancet 336 1990 225 229
12. M.V. Relling, M.L. Hancock, G.K. Rivera, J.T. Sandlund, R.C. Ribeiro, and E.Y. Krynetski Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus J. Natl. Cancer Inst. 91 1999 2001 2008
13. L. Lennard The clinical pharmacology of 6-mercaptopurine Eur. J. Clin. Pharmacol. 43 1992 329 339
14. T. Dervieux, J.G. Blanco, E.Y. Krynetski, E.F. Vanin, M.F. Roussel, and M.V. Relling Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells Cancer Res. 61 2001 5810 5816
15. I. Tiede, G. Fritz, S. Strand, D. Poppe, R. Dvorsky, and D. Strand CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes J. Clin. Invest. 111 2003 1133 1145
16. R.M. Weinshilboum, and S.L. Sladek Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity Am. J. Hum. Genet. 32 1980 651 662
17. H.L. Tai, E.Y. Krynetski, C.R. Yates, T. Loennechen, M.Y. Fessing, and N.F. Krynetskaia Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians Am. J. Hum. Genet. 58 1996 694 702
18. C.R. Yates, E.Y. Krynetski, T. Loennechen, M.Y. Fessing, H.L. Tai, and C.-H. Pui Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance Ann. Int. Med. 126 1997 608 614
19. D. Otterness, C. Szumlanski, L. Lennard, B. Klemetsdal, J. Aarbakke, and J.O. Park-Hah Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms Clin. Pharmacol. Ther. 62 1997 60 73
20. H.L. Tai, E.Y. Krynetski, E.G. Schuetz, Y. Yanishevski, and W.E. Evans Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity Proc. Natl. Acad. Sci. U.S.A. 94 1997 6444 6449
21. H.-L. Tai, M. Fessing, E.J. Bonten, Y. Yanishevski, A. d'Azzo, E. Krynetski, and W.E. Evans Enhanced proteosomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C Pharmacogenetics 9 1999 641 650
22. L. Lennard, B.E. Gibson, T. Nicole, and J.S. Lilleyman Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia Arch. Dis. Child 69 1993 577 579
23. T. Dervieux, Y. Medard, P. Verpillat, V. Guigonis, M. Duval, B. Lescoeur, S. Suciu, E Vilmer, and E Jacqz-Aigrain Possible implication of thiopurine S-methyltransferase in the occurrence of infectious episodes during maintenance therapy of acute leukemia with mercaptopurine Leukemia 15 11 2001 1706 1712
24. W. Tassaneeyakul, S. Srimarthpirom, S. Reungjui, K. Chansung, and A. Romphruk Azathioprine-induced fatal myelosuppression in a renal-transplant recipient who carried heterozygous TPMT* 1/*3C Transplantation 76 2003 265 266
25. E. Schutz, J. Gummert, F. Mohr, and M. Oellerich Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient Lancet 341 1993 436
26. K.T. Oh, A.H. Anis, and S.C. Bae Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea Rheumatology (Oxford) 43 2004 156 163
27. C.A. Marra, J.M. Esdaile, and A.H. Anis Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine J. Rheumatol. 29 2002 2507 2512
28. M.V. Relling, M.L. Hancock, J.M. Boyett, C.-H. Pui, and W.E. Evans Prognostic importance of 6- mercaptopurine dose intensity in acute lymphoblastic leukemia Blood 93 1999 2817 2823
29. C. Cuffari, T. Dassopoulos, L. Turnbough, R.E. Thompson, and T.M. Bayless Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease Clin. Gastroenterol. Hepatol. 2 2004 410 417
30. U. Nygaard, N. Toft, and K. Schmiegelow Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity Clin. Pharmacol. Ther. 75 2004 274 281
31. M.C. Dubinsky, H. Yang, P.V. Hassard, E.G. Seidman, L.Y. Kam, and M.T. Abreu 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease Gastroenterology 122 2002 904 915
32. A.M. Marinaki, A. Ansari, J.A. Duley, M. Arenas, S. Sumi, and C.M. Lewis Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase) Pharmacogenetics 14 2004 181 187
33. J.M. Kremer Toward a better understanding of methotrexate Arth. Rheum. 50 2004 1370 1382
34. I.D. Goldman, N.S. Lichtenstein, and V.T. Oliverio Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell J. Biol. Chem. 243 1968 5007 5017
35. L.H. Matherly, and D.I. Goldman Membrane transport of folates Vit. Horm. 66 1904 403 456
36. R. Gorlick, E. Goker, T. Trippett, M. Waltham, D. Banerjee, and J.R. Bertino Intrinsic and acquired resistance to methotrexate in acute leukemia N. Engl. J. Med. 335 1996 1041 1048
37. B.A. Chabner, C.J. Allegra, G.A. Curt, N.J. Clendeninn, J. Baram, and S. Koizumi Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76 1985 907 912
38. L. Morabito, M.C. Montesinos, D.M. Schreibman, L. Balter, L.F. Thompson, and R. Resta Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides J. Clin. Invest. 101 1998 295 300
39. M.C. Montesinos, A. Desai, D. Delano, J.F. Chen, J.S. Fink, and M.A. Jacobson Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68 Arth. Rheum. 48 2003 240 247
40. B.N. Cronstein, D. Naime, and E. Ostad The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation J. Clin. Invest. 92 1993 2675 2682
41. P. Frosst, H.J. Blom, R. Milos, P. Goyette, C.A. Sheppard, and R.G. Matthews A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase Nat. Genet. 10 1995 111 113
42. P. Goyette, J.S. Sumner, R. Milos, A.M. Duncan, D.S. Rosenblatt, and R.G. Matthews Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification Nat. Genet. 7 1994 195 200
43. C.M. Ulrich, Y. Yasui, R. Storb, M.M. Schubert, J.L. Wagner, and J. Bigler Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism Blood 98 2001 231 234
44. A.M. Molloy, S. Daly, J.L. Mills, P.N. Kirke, A.S. Whitehead, and D. Ramsbottom Thermolabile variant of 5, 10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations Lancet 349 1997 1591 1593
45. K. Robien, M.M. Schubert, B. Bruemmer, M.E. Lloid, J.D. Potter, and C.M. Ulrich Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia J. Clin. Oncol. 22 2004 1268 1275
46. P. Chiusolo, G. Reddiconto, I. Casorelli, L. Laurenti, F. Sora, and L. Mele Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate Ann. Oncol. 13 2002 1915 1918
47. W. Urano, A. Taniguchi, H. Yamanaka, E. Tanaka, H. Nakajima, and Y. Matsuda Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses Pharmacogenetics 12 2002 183 190
48. A.E. van Ede, R.F. Laan, H.J. Blom, T.W. Huizinga, C.J. Haagsma, and B.A. Giesendorf The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients Arth. Rheum. 44 2001 2525 2530
49. T. Dervieux, D.E. Furst, D. Orentas, R. Lein, K. Capps, M. Smith, J.M. Walsh, and Kremer Polyglutamation of methotrexate with common polymorphism in reduced folate carrier, AICAR transformylase and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis Arth. Rheum. 50 9 2004 2766 2774
50. Y. Goto, L. Yue, A. Yokoi, R. Nishimura, T. Uehara, and S. Koizumi A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression Clin. Cancer Res. 7 2001 1952 1956
51. Z.S. Chen, K. Lee, S. Walther, R.B. Raftogianis, M. Kuwano, and H. Zeng Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system Cancer Res. 62 2002 3144 3150
52. K. Lee, A.J. Klein-Szanto, and G.D. Kruh Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells J. Natl. Cancer Inst. 92 2000 1934 1940
53. A.M. Pellino, and P.V. Danenberg Evidence from chemical degradation studies for a covalent bond from 5-fluoro-2′-deoxyuridylate to N-5 of tetrahydrofolate in the ternary complex of thymidylate synthetase-5-fluoro- 2′-deoxyuridylate-5,10-methylenetetrahydrofolate J. Biol. Chem. 260 1985 10996 11000
54. H.M. Pinedo, and G.F. Peters Fluorouracil: biochemistry and pharmacology J. Clin. Oncol. 6 1988 1653 1664
55. G.D. Heggie, J.P. Sommadossi, D.S. Cross, W.J. Huster, and R.B. Diasio Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile Cancer Res. 47 1987 2203 2206
56. M.C. Etienne, J.L. Lagrange, O. Dassonville, R. Fleming, A. Thyss, and N. Renee Population study of dihydropyrimidine dehydrogenase in cancer patients J. Clin. Oncol. 12 1994 2248 2253 (see comments)
57. Z. Lu, R. Zhang, and R.B. Diasio Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy Cancer Res. 53 1993 5433 5438
58. M.R. Johnson, A. Hageboutros, K. Wang, L. High, J.B. Smith, and R.B. Diasio Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil Clin. Cancer Res. 5 1999 2006 2011
59. R.B. Diasio, T.L. Beavers, and J.T. Carpenter Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity J. Clin. Invest. 81 1988 47 51
60. F.J. Gonzalez, and P. Fernandez-Salguero Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency Trends Pharmacol. Sci. 16 1995 325 327
61. R. Berger, S.A. Stoker-de Vries, S.K. Wadman, M. Duran, F.A. Beemer, and P.K. de Bree Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism Clin. Chim. Acta 141 1984 227 234
62. X. Wei, H.L. McLeod, J. McMurrough, F.J. Gonzalez, and P. Fernandez-Salguero Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity J. Clin. Invest. 98 1996 610 615
63. A.B. Van Kuilenburg, E.W. Muller, J. Haasjes, R. Meinsma, L. Zoetekouw, and H.R. Waterham Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency Clin. Cancer Res. 7 2001 1149 1153
64. H.L. McLeod, E.S. Collie-Duguid, P. Vreken, M.R. Johnson, X. Wei, and A. Sapone Nomenclature for human DPYD alleles Pharmacogenetics 8 1998 455 459
65. T. Hori, E. Takahashi, D. Ayusawa, K. Takeishi, S. Kaneda, and T. Seno Regional assignment of the human thymidylate synthase (TS) gene to chromosome band 18p11.32 by nonisotopic in situ hybridization Hum. Genet. 85 1990 576 580
66. E. Villafranca, Y. Okruzhnov, M.A. Dominguez, J. Garcia-Foncillas, I. Azinovic, and E. Martinez Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer J. Clin. Oncol. 19 2001 1779 1786
67. S. Marsh, J.A. McKay, J. Cassidy, and H.L. McLeod Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer Int. J. Oncol. 19 2001 383 386
68. P.G. Johnston, H.J. Lenz, C.G. Leichman, K.D. Danenberg, C.J. Allegra, and P.V. Danenberg Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res. 55 1995 1407 1412
69. C.G. Leichman, H.J. Lenz, L. Leichman, K. Danenberg, J. Baranda, and S. Groshen Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin J. Clin. Oncol. 15 1997 3223 3229
70. K. Kawakami, K. Omura, E. Kanehira, and Y. Watanabe Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers Anticancer Res. 19 1999 3249 3252
71. N. Horie, H. Aiba, K. Oguro, H. Hojo, and K. Takeishi Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase Cell Struct. Funct. 20 1995 191 197
72. V. Cohen, V. Panet-Raymond, N. Sabbaghian, I. Morin, G. Batist, and R. Rozen Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy Clin. Cancer Res. 9 2003 1611 1615
73. P. Rougier, E. Van Cutsem, E. Bajetta, N. Niederle, K. Possinger, and R. Labianca Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1998 1407 1412
74. Y. Kawato, M. Aonuma, Y. Hirota, H. Kuga, and K. Sato Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 51 1991 4187 4191
75. P.J. Bosma, J.R. Chowdhury, C. Bakker, S. Gantla, A. De Boer, and B.A. Oostra The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome N. Engl. J. Med. 333 1995 1171 1175
76. E. Gupta, T.M. Lestingi, R. Mick, J. Ramirez, E.E. Vokes, and M.J. Ratain Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea Cancer Res. 54 1994 3723 3725
77. Y. Ando, H. Saka, M. Ando, T. Sawa, K. Muro, and H. Ueoka Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res. 60 2000 6921 6926
78. L. Iyer, C.D. King, P.F. Whitington, M.D. Green, S.K. Roy, and T.R. Tephly Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1 A1 in the glucuronidation of its active metabolite (SN- 38) in human liver microsomes J. Clin. Invest. 101 1998 847 854
79. L. Iyer, D. Hall, S. Das, M.A. Mortell, J. Ramirez, and S. Kim Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin. Pharmacol. Therap. 65 1999 576 582
80. M.B. Fisher, M. Vandenbranden, K. Findlay, B. Burchell, K.E. Thummel, and S.D. Hall Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank Pharmacogenetics 10 2000 727 739
81. J.K. Ritter, M.T. Yeatman, P. Ferreira, and I.S. Owens Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient J. Clin. Invest. 90 1992 150 155
82. O. Koiwai, S. Aono, Y. Adachi, T. Kamisako, Y. Yasui, and M. Nishizawa Crigler-Najjar syndrome type II is inherited both as a dominant and as a recessive trait Hum. Mol. Genet. 5 1996 645 647
83. F. Innocenti, S.D. Undevia, L. Iyer, P.X. Chen, S. Das, and M. Kocherginsky Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropeniaofirinotecan J. Clin. Oncol. 22 2004 1382 1388
84. E. Wasserman, A. Myara, F. Lokiec, F. Goldwasser, F. Trivin, and M. Mahjoubi Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports Ann. Oncol. 8 2000 1049 1051
85. R. Humerickhouse, K. Lohrbach, L. Li, W.F. Bosron, and M.E. Dolan Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2 Cancer Res. 60 2000 1189 1192
86. R. Khanna, C.L. Morton, M.K. Danks, and P.M. Potter Proficient metabolism of irinotecan by a human intestinal carboxylesterase Cancer Res. 60 2000 4725 4728
87. R.H. Mathijssen, S. Marsh, M.O. Karlsson, R. Xie, S.D. Baker, and J. Verweij Irinotecan pathway genotype analysis to predict pharmacokinetics Clin. Cancer Res. 9 2003 3246 3253
88. D. Werck-Reichhart, R. Feyereisen, and Cytochromes P450: a success story Genome Biol. 1 6 2000 Dec 08
89. H. Takahashi, and H. Echizen Pharmacogenetics of warfarin elimination and its clinical implications Clin. Pharmacokinet. 40 1904 587 603
90. H. Takahashi, and H. Echizen Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin Pharmacogenomics J. 3 1904 202 214
91. M.K. Higashi, D.L. Veenstra, L.M. Kondo, A.K. Wittkowsky, S.L. Srinouanprachanh, and F.M. Farin Association between CYP2C9 genetic variants and anti-coagulation-related outcomes during warfarin therapy JAMA 287 2002 1690 1698
92. A.E. Rettie, L.C. Wienkers, F.J. Gonzalez, W.F. Trager, K.R. Korzekwa, and Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 Pharmacogenetics 4 1994 39 42
93. R.L. Haining, A.P. Hunter, M.E. Veronese, W.F. Trager, and A.E. Rettie Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms Arch. Biochem. Biophys. 333 1996 447 458
94. H. Takahashi, T. Kashima, S. Nomoto, K. Iwade, H. Tainaka, and T. Shimizu Comparisons between in vitro and in vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes Pharmacogenetics 8 1998 365 373
95. M.K. Higashi, D.L. Veenstra, L.M. Kondo, A.K. Wittkowsky, S.L. Srinouanprachanh, and F.M. Farin Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 2002 1690 1698
96. S. Mallal, D. Nolan, C. Witt, G. Masel, A.M. Martin, and C. Moore Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 359 2002 727 732
97. S. Hetherington, A.R. Hughes, M. Mosteller, D. Shortino, K.L. Baker, and W. Spreen Genetic variations in HLA-B region and hypersensitivity reactions to abacavir Lancet 359 2002 1121 1122
98. F. Davidoff The heartbreak of drug pricing Ann. Int. Med. 134 2001 1068 1071
99. H.G. Grabowski, and J. Vernon The distribution of sales revenues from pharmaceutical innovation Pharmacoeconomics 18 suppl. 1 2000 21 32
100. J. Johnson Democrats Demand Medicare Coverage, price Control for Rx drugs. CNN News.com cybercast News Services, 6-24-2002.
101. J. Oberlander, J. Jaffe, Next step: drug pricing controls, Washington Post, vol. B07, 2003, pp. 12-14.
102. M.K. Ma, M.H. Woo, and H.L. McLeod Genetic basis of drug metabolism Am. J. Health Syst. Pharm. 59 2002 2061 2069
103. H.L. McLeod Race and responsiveness to drugs for heart failure N. Engl. J. Med. 345 2001 766 767
104. S.E. Beltz, G.C. Yee, Pharmacoeconomics of cancer therapy. Cancer Control EDAT-2000/04/13 MHDA-2000/04/13 PST-publish (1998) vol. 5, pp. 415-424.
105. P.E. Greenberg, A. Arcelus, H.G. Birnbaum, P.Y. Cremieux, J. LeLorier, and P. Ouellette Pharmacoeconomics and health policy. Current applications and prospects for the future Pharmacoeconomics 16 1999 425 432
106. P.P. Leung, I.F. Tannock, A.M. Oza, A. Puodziunas, and G. Dranitsaris Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer J. Clin. Oncol. 17 1999 3082 3090
107. Chemotherapy sensitivity and resistance assays. Blue Cross Blue Shield Technology Evaluation, Center Assessment Program 17, 12.2002.
108. J.P. Kassirer, A.J. Moskowitz, J. Lau, and S.G. Pauker Decision analysis: a progress report Ann. Int. Med. 106 1987 275 291
109. C.A. Marra, J.M. Esdaile, and A.H. Anis Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine J. Rheumatol. 29 2002 2507 2512
110. D.A. Hughes, F.J. Vilar, C.C. Ward, A. Alfirevic, B.K. Park, and M. Pirmohamed Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity Pharmacogenetics 14 2004 335 342